Regenerative medicine is going from strength to strength, with over 50 RMAT designations in the US to date, successful development of autologous stem cell treatments and renewed interest from the aesthetics industry. Gene therapies continue to show promise and inch closer to adoption. It is an incredibly exciting time to be a part of the growing longevity community with cell & gene pioneers expanding age-related solutions such as novel neural stem cell therapy, muscle tissue constructs and gene modifiers for macular degeneration.
Meanwhile longevity science is at a critical moment in time. In the wake of the COVID-19 pandemic investors, regulators and the medical community have woken up to the promise of ageing science and its potential to completely change how we prevent and treat disease. Advanced analytical tools are driving huge strides in our understanding of ageing biology and potential targets, and a number of high-profile fund raises are driving investor interest in the space.
Regenerative medicine and longevity therapeutics have both come a long way in recent years and set for the next decade of innovation, particularly with both gaining from parallel advancements in ageing science. The deeper understanding in cellular senescence, identification of aging genes, tissue engineering constructs and advancements in RNA modulation are all allowing longevity science and cell & gene therapies space to learn and innovate together.
The Longevity Leaders World Congress brings the world’s most prominent regenerative medicine and longevity scientists together, presenting the new research, responsible drug development, novel therapies and commercialisation to target age-related diseases. We’d love you to join us!
